Pfizer Stock Watch: New Drug Trials Aim to Reignite Growth

Pfizer ( (PFE) ) has been popular among investors this week. Here is a recap of the key news on this stock.

Pfizer is quietly rebuilding its post-COVID growth story with a wave of early- and mid-stage pipeline updates that could shape the company’s long-term revenue mix. In cardiovascular disease, Pfizer has launched a Phase 1 trial in China of PF-07328948, an oral candidate aimed at heart failure, to study its pharmacokinetics, safety, and tolerability in healthy Chinese adults after multiple daily doses. The study is open-label, uses a single treatment group, and is still in the start-up phase with recruitment yet to begin, underscoring how early this asset is in development.

In a parallel Phase 1 program, Pfizer is running a single-dose, open-label study of PF-07328948 in adults with varying degrees of renal impairment and in healthy volunteers, seeking to understand dosing needs in patients with kidney issues. This renal study is already recruiting and involves up to 64 days of follow-up, showing methodical groundwork on safety and drug handling rather than immediate efficacy signals.

Beyond cardiology, Pfizer is advancing a subcutaneous obesity drug, PF-08653944, in a Phase 1 trial that tests injection into the abdomen, thigh, and upper arm to map absorption and early safety, positioning the company in a market currently dominated by Eli Lilly and Novo Nordisk. Although these early data are unlikely to move near-term earnings, success could add a new, high-demand growth driver and help diversify Pfizer’s portfolio.

The company is also preparing a Phase 2, double-blind mRNA flu vaccine study comparing six experimental shots with a standard flu vaccine, part of its effort to build a durable mRNA franchise beyond COVID and challenge players like Moderna, Sanofi, and GSK. While still a multi-year story, positive flu data would bolster confidence in Pfizer’s innovation engine and support sentiment around its long-term competitive position.

Closer to commercialization, Pfizer has completed its Phase 3 Tranquillo trial of ritlecitinib in nonsegmental vitiligo, with 52-week data under review and the study status updated to completed on February 25, 2026. If ritlecitinib delivers strong skin repigmentation and a clean safety profile, it could underpin regulatory filings in dermatology and open a new immunology revenue stream, offering one of the clearer medium-term catalysts for PFE shares.

For investors tracking Pfizer’s stock, these updates are incremental rather than immediate game-changers, but they collectively highlight a broad attempt to rebuild and diversify the pipeline after the COVID vaccine windfall. Continued progress across cardiology, obesity, vaccines, and dermatology will be key for restoring growth expectations and could gradually improve valuation if clinical results and regulatory milestones break in Pfizer’s favor over the next several years.